Source link : https://www.newshealth.biz/health-news/pfs-benefits-seen-with-palbociclib-endocrine-therapy-in-bc/
Premenopausal patients with hormone receptor positive, HER2 negative (HR+/HER2-) metastatic breast cancer (mBC) continued to show consistent benefit when treated with CDK4/6 inhibition plus endocrine therapy compared with chemotherapy, according to updated survival outcomes of the Young-PEARL study. “The combination of palbociclib plus exemestane plus leuprolide showed a consistent significant improvement in PFS [progression-free survival] […]
Author : News Health
Publish date : 2024-07-11 07:57:52
Copyright for syndicated content belongs to the linked Source.
Categories